|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Fusion protein containing the extracellular part of TRAIL-R1 and the constant part of the heavy chain of the human IgG1.|
|Storage buffer||PBS, pH 7.4|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 ug/ml|
|Functional Assay (FN)||Assay Dependent|
|Immunocytochemistry (ICC)||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunocytochemistry (ICC)||See 1 publications below|
Endotoxin level is less than 0.01 EU/ug of the protein, as determined by the LAL test.
TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1. The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues.
Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
MA1-19025 was used in immunocytochemistry to investigate the role of upstream events in the extrinsic apoptotic pathway for cisplatin and a potent platinum (IV) complex-mediated enhancement of TRAIL-induced cancer cells killing
|Vondálová Blanárová O,Jelínková I,Szöor A,Skender B,Soucek K,Horváth V,Vaculová A,Andera L,Sova P,Szöllosi J,Hofmanová J,Vereb G,Kozubík A||Carcinogenesis (32:42)||2011|